Header Logo

Connection

PEDRO PIEDRA to Respiratory Syncytial Virus Vaccines

Back to Details
This is a "connection" page, showing publications PEDRO PIEDRA has written about Respiratory Syncytial Virus Vaccines.
PEDRO PIEDRA
Connection Strength
5.670
Respiratory Syncytial Virus Vaccines
  1. The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent. J Virol. 2023 05 31; 97(5):e0025423.
    View in: PubMed
    Score: 0.758
  2. Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein. Vaccine. 2022 01 24; 40(3):536-543.
    View in: PubMed
    Score: 0.688
  3. Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine. Expert Rev Vaccines. 2021 04; 20(4):351-364.
    View in: PubMed
    Score: 0.659
  4. A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas. Vaccine. 2021 02 22; 39(8):1248-1256.
    View in: PubMed
    Score: 0.648
  5. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013 Jan 07; 31(3):524-32.
    View in: PubMed
    Score: 0.367
  6. Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats. Vaccine. 2025 May 22; 56:127183.
    View in: PubMed
    Score: 0.218
  7. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
    View in: PubMed
    Score: 0.201
  8. Future directions in vaccine prevention of respiratory syncytial virus. Pediatr Infect Dis J. 2002 May; 21(5):482-7.
    View in: PubMed
    Score: 0.177
  9. Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection. Vaccine. 2021 07 05; 39(30):4063-4071.
    View in: PubMed
    Score: 0.166
  10. Respiratory syncytial virus vaccines: recent developments. Pediatr Infect Dis J. 2000 Aug; 19(8):805-8; discussion 809-10.
    View in: PubMed
    Score: 0.157
  11. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. N Engl J Med. 2020 07 30; 383(5):426-439.
    View in: PubMed
    Score: 0.156
  12. Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants. J Infect Dis. 2019 10 22; 220(11):1802-1815.
    View in: PubMed
    Score: 0.148
  13. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine. 2018 12 18; 36(52):8069-8078.
    View in: PubMed
    Score: 0.139
  14. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018 10; 18(10):e295-e311.
    View in: PubMed
    Score: 0.135
  15. Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field. Viral Immunol. 2018 03; 31(2):195-203.
    View in: PubMed
    Score: 0.131
  16. Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines. Clin Infect Dis. 2017 Sep 15; 65(6):1020-1025.
    View in: PubMed
    Score: 0.128
  17. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. 2017 06 27; 35(30):3749-3759.
    View in: PubMed
    Score: 0.126
  18. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. PLoS One. 2017; 12(4):e0175792.
    View in: PubMed
    Score: 0.125
  19. A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nat Commun. 2016 12 21; 7:13916.
    View in: PubMed
    Score: 0.122
  20. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol. 2016 08 15; 90(16):7508-7518.
    View in: PubMed
    Score: 0.118
  21. Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol Med. 2014 Nov; 6(11):1436-54.
    View in: PubMed
    Score: 0.105
  22. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. J Virol. 2014 May; 88(9):5100-8.
    View in: PubMed
    Score: 0.100
  23. Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged <5 Years: New Vaccine Surveillance Network, United States, 2016-2020. Clin Infect Dis. 2024 05 15; 78(5):1352-1359.
    View in: PubMed
    Score: 0.051
  24. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine. 2003 Jul 28; 21(24):3465-7.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.